Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAFALDA-R: Rilpivirine for Liver Fibrosis in HIV
NCT05898841Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rilpivirine in human immunodeficiency virus infection (HIV), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Fundación SEIMC-GeSIDA. Started May 2023; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT05898841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898841.